|
Bone Marrow Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
Furthermore, the ANT group had worse myelopathy scores (mJOAS<sub>ANT group</sub> = 13.5 ± 2.5, mJOAS<sub>A/P group</sub> = 15.7 ± 2.2).
|
29916066 |
2019 |
|
Schizophrenia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Expression of SLC25A1-SLC25A4 interactome components was affected in neuronal cells from schizophrenia patients.
|
30833507 |
2019 |
|
Spinal Cord Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
Furthermore, the ANT group had worse myelopathy scores (mJOAS<sub>ANT group</sub> = 13.5 ± 2.5, mJOAS<sub>A/P group</sub> = 15.7 ± 2.2).
|
29916066 |
2019 |
|
Hypothalamic hamartomas
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
ABBREVIATIONS AED = antiepileptic drug; ANT = anterior nucleus of the thalamus; BOLD = blood oxygen level dependent; CCEP = cortico-cortical evoked potential; DBS = deep brain stimulation; ECoG = electrocorticography; ERSET = Early Randomized Surgical Epilepsy Trial; FCD = focal cortical dysplasia; HH = hypothalamic hamartoma; LITT = laser interstitial thermal therapy; RCT = randomized controlled trial; r-fMRI = resting-state functional MRI; RNS = responsive neurostimulation; SEEG = stereo-electroencephalography; VNS = vagus nerve stimulation.
|
30970205 |
2019 |
|
Respiratory syncytial virus (RSV) infection in conditions classified elsewhere and of unspecified site
|
0.010 |
Biomarker
|
disease |
BEFREE |
One clinical isolate (BE/ANT-A11/17) replicated very efficiently in all cell lines, and remarkably, even better than RSV A2 in the HEp-2 cell line.
|
31698728 |
2019 |
|
Drug Resistant Epilepsy
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
This is the first study in which favorable outcomes of ANT-DBS surgery were observed in individual patients with refractory epilepsy who had not responded to prior VNS.
|
31533117 |
2019 |
|
Aphasia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The primary outcome measures for changes in language performance were the Western Aphasia Battery's aphasia quotient AQ; the secondary outcome measures were the Boston naming test (BNT) and the Action naming test (Action BNT, ANT).All subjects completed the study.
|
30778280 |
2018 |
|
Multiple Sclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Cognitive outcomes were tested by composite scores measuring change in performance on standard tests (Brief International Cognitive Assessment in MS or BICAMS), basic attention (ANT-I Orienting and Attention Networks, Cogstate Detection), complex attention (ANT-I Executive Network, Cogstate Identification and One-Back), and intra-individual response variability (ANT-I and Cogstate identification; sensitive markers of disease status).
|
28225155 |
2018 |
|
Erythema
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
A higher concentration of the ANT1 cream significantly reduces wrinkles and redness after laser.
|
29369914 |
2018 |
|
Hyperlactatemia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The phenotype of recessive SLC25A4 (ANT1) mutations although rare, is homogenous and easily recognizable and could help orientate the molecular analysis in adults with exercise intolerance associated with hyperlactatemia.
|
28823815 |
2018 |
|
Cardiac Arrest
|
0.010 |
Biomarker
|
disease |
BEFREE |
SCA type 6 showed lower metabolic ratios in almost all cerebellar subregions (ANT, 0.57 ± 0.06, p < 0.001) except INFV.
|
28319124 |
2017 |
|
Metabolic Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
Hence, increased oxidation of dietary-reducing equivalents by elevated muscle mitochondrial respiration appears to be the mechanism by which ANT1-deficient mice prevent diabetes, demonstrating that the rate of mitochondrial oxidation of calories is important in the etiology of metabolic disease.
|
28223503 |
2017 |
|
Neuroendocrine Tumors
|
0.010 |
Biomarker
|
group |
BEFREE |
A somatostatin receptor (SSTR)-targeting antagonist peptide (sst<sub>2</sub>-ANT) was radiolabeled with <sup>99m</sup>Tc tricarbonyl via a tridentate [N,S,N]-type ligand (L) to develop a radiodiagnostic agent, <sup>99m</sup>TcL-sst<sub>2</sub>-ANT, for imaging of SSTR-expressing neuroendocrine tumors.
|
28043006 |
2017 |
|
Alzheimer's Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
We reported that a 20-22 kDa NH2-tau fragment mapping between 26 and 230 amino acids of the longest human tau isoform (aka NH2htau): (i) is detectable in cellular and animal AD models, as well in synaptic mitochondria and cerebrospinal fluids (CSF) from human AD subjects; (ii) is neurotoxic in primary hippocampal neurons; (iii) compromises the mitochondrial biology both directly, by inhibiting the ANT-1-dependent ADP/ATP exchange, and indirectly, by impairing their selective autophagic clearance (mitophagy).
|
25687137 |
2015 |
|
Protein Misfolding Disorders
|
0.010 |
Biomarker
|
disease |
BEFREE |
The data suggest that the Ant1-induced diseases belong to protein misfolding disorders.
|
25833713 |
2015 |
|
Major Depressive Disorder
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
There were no differences between the two at-risk groups (i.e., youth with BD parent vs. youth with MDD parent) on any ANT-S measure.
|
22980403 |
2013 |
|
Malignant neoplasm of breast
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Also, miRNA expression profiles of the BC and their corresponding ANT were evaluated.
|
22524830 |
2012 |
|
Breast Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Also, miRNA expression profiles of the BC and their corresponding ANT were evaluated.
|
22524830 |
2012 |
|
Parkinsonian Disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
Mutations in the progressive external ophthalmoplegia 1 (PEO1), adenine nucleotide translocator 1 (ANT1) and DNA polymerase gamma (POLG) genes were reported in patients with progressive external ophthalmoplegia and parkinsonism.
|
21301859 |
2011 |
|
Carcinogenesis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Unlike the ANT1 and ANT3 isoforms, ANT2 is not pro-apoptotic and may therefore contribute to carcinogenesis.
|
20950584 |
2011 |
|
Rett Syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
As both ANT1 mutations and overexpression have been associated with human diseases, we consider it highly relevant to address the consequences of ANT1 deregulation in Rett syndrome.
|
20504995 |
2010 |
|
Malignant Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
Our results suggest that ANT1 transfection may be a useful therapeutic modality for the treatment of cancer.
|
18522758 |
2008 |
|
Primary malignant neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
Our results suggest that ANT1 transfection may be a useful therapeutic modality for the treatment of cancer.
|
18522758 |
2008 |
|
Photoreceptor degeneration
|
0.010 |
Biomarker
|
disease |
BEFREE |
Recently, the dominant negative pathogenic mechanism in the TG model was shown to involve increased affinity of the truncated mutant HRG4 for its target, ARL2, which leads to a delayed decrease in its downstream target, mitochondrial ANT1, mitochondrial stress, synaptic degeneration, trans-synaptic degeneration, and whole photoreceptor degeneration by apoptosis.
|
17174953 |
2007 |
|
Cardiomyopathy, Familial Idiopathic
|
0.010 |
Biomarker
|
disease |
BEFREE |
The altered isoform expression in DCM hearts entails changes in the kinetic properties of total ANT protein restricting ANT function and contributing to disturbed energy metabolism in DCM.
|
16107323 |
2006 |